NBY
NovaBay Pharmaceuticals Inc
NYSE MKT: NBY · HEALTHCARE · BIOTECHNOLOGY
$1.95
+22.64% today
Updated 2026-04-02
Market cap
$51.92M
P/E ratio
—
P/S ratio
0.16x
EPS (TTM)
$-28.50
Dividend yield
—
52W range
$1 – $100
Volume
1.3M
NovaBay Pharmaceuticals Inc (NBY) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
350.10%
ROE
-516.00%
ROA
-76.10%
Debt/equity
0.59x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $1.53M | $-5.29M | 100.00% | -360.47% | -344.81% |
| 2007 | $5.91M | $-5.40M | 100.00% | -99.37% | -91.32% |
| 2008 | $6.72M | $-8.11M | 100.00% | -126.58% | -120.71% |
| 2009 | $15.68M | $2.70M | 100.00% | 17.47% | 17.20% |
| 2010 | $9.75M | $-4.31M | 100.00% | -46.30% | -44.17% |
| 2011 | $11.02M | $-5.08M | 100.00% | -39.21% | -46.15% |
| 2012 | $6.95M | $-7.03M | 99.88% | -119.61% | -101.15% |
| 2013 | $3.48M | $-16.04M | 95.34% | -445.38% | -461.37% |
| 2014 | $1.05M | $-15.19M | 53.89% | -1,601.33% | -1,441.56% |
| 2015 | $4.38M | $-18.97M | 71.22% | -479.66% | -433.07% |
| 2016 | $11.90M | $-13.15M | 79.29% | -92.31% | -110.54% |
| 2017 | $18.23M | $-7.40M | 84.73% | -40.10% | -40.61% |
| 2018 | $12.51M | $-6.54M | 87.98% | -62.93% | -52.33% |
| 2019 | $6.60M | $-9.66M | 73.66% | -142.45% | -146.36% |
| 2020 | $9.93M | $-11.04M | 60.04% | -64.69% | -111.12% |
| 2021 | $10.20M | $-5.82M | 63.85% | -86.85% | -57.08% |
| 2022 | $14.40M | $-10.61M | 54.02% | -100.09% | -73.65% |
| 2023 | $10.46M | $-9.64M | 58.19% | -39.23% | -92.20% |
| 2024 | $9.78M | $-7.22M | 66.26% | -59.70% | -73.85% |
| 2025 | $0.00 | $-22.14M | — | — | — |